Company News: Curetis to Raise EUR 4.1 Million in Equity Offering with Access to Additional USD 10 million in Equity Over 36 Months

– Company to Issue 854,166 New Shares at EUR 4.80 Per Share

This announcement contains inside information within the meaning of article 7(1) of the EU Market Abuse Directive.

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has obtained commitments from qualified investors in Europe and the United States to subscribe for 854,166 new ordinary shares (the “Offer Shares”) of the Company (the “Offering”).

Total gross proceeds from the Offering for the Company are expected to be EUR 4.1 million, before deducting fees and expenses.

The Company also secured an additional USD 10 million equity facility offered by Global Corporate Finance (GCF), New York, NY, USA, allowing the Company solely at its request to raise additional equity over a period of up to 36 months subject to certain pre-agreed floor pricing.

Curetis expects to use the proceeds from the Offering as well as potentially from the equity facility by GCF to advance key commercial and R&D initiatives and for general corporate purposes, including:

  • support of the U.S. commercial launch and roll-out of the Unyvero platform and Unyvero LRT Application Cartridge;
  • driving the continued commercial roll-out of the Unyvero platform and Unyvero Application Cartridges in key EMEA markets;
  • ongoing research and development projects aimed at expanding the product menu and platform capabilities of Unyvero and Ares Genetics.

“This offering strengthens our shareholder base in both the U.S. and Europe through the addition of several high-caliber healthcare-focused institutional investors. Also, with the additional USD 10 million equity facility offered by Global Corporate Finance we have added great flexibility to raise additional equity. We believe that the success of this offering reflects the progress we have made in advancing the Company since its IPO and investors’ excitement over the opportunities that lie ahead,” said Oliver Schacht, Ph.D., CEO of Curetis. “We have seen a number of significant catalysts for growth, notably the recent U.S. FDA clearance of our Unyvero System and LRT cartridge. The proceeds of this financing will provide us with the means to ensure an optimal U.S. commercial launch for Unyvero, further accelerate the EMEA commercial roll-out of the Unyvero platform and continue innovating by supporting the ongoing evolution of the Unyvero platform and Ares Genetics’ activities.”

Settlement and Admission of the Offer Shares

Payment for the Offer Shares is expected to take place on 30 April 2018 with delivery expected on 2 May 2018 or shortly thereafter, at which date the Offer Shares are also expected to be admitted to listing and trading on Euronext Amsterdam and Euronext Brussels under
ISIN NL0011509294 and ticker symbol CURE.

Following completion of the Offering, the Company’s issued share capital amounts to
EUR 163,925.77, consisting of 16,392,577 ordinary shares with a nominal value of EUR 0.01 each.